78278343PCR3003 A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

by Mary Beth Wilwerding | Sep 3, 2026

V940-011 A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

by Mary Beth Wilwerding | Sep 3, 2026

MK5684-004 Phase 3, Randomized Study of MK-5684 vs alternative aberatarone acetate or enzalutamide in participants with metastatic castration resistant prostate cancer that progressed on or after prior treatment with one next-generation hormonal agent

by Mary Beth Wilwerding | Aug 19, 2026

MK6482-033 A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

by Mary Beth Wilwerding | Aug 19, 2026

NEO-811-101 An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and ExpansionStudy of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable ClearCell Renal Cell Carcinoma​

by Mary Beth Wilwerding | Aug 19, 2026